Erratum to: The need of standardization and of large clinical studies in an emerging indication of [18 F]FDG PET: the autoimmune encephalitis

Abstract

The author name Lida Jafari Saraf in the original version of this article should be change to Lida Jafari.

Modeling the Effects of Age and Sex on Normal Pediatric Brain Metabolism Using18F-FDG PET/CT

“…In particular, these models provide an age and sex reference standard that can then be used to aid in the interpretation of individual pediatric 18 F-FDG PET brain studies for patients with central nervous system disease. For example, these models can be directly applicable to the interpretation of epilepsy studies (12,22), neurooncology cases, or patients with infectious or inflammatory brain diseases such as encephalitis, for either diagnosis or follow-up (23,24,25). Our method offers an alternative to the more time-consuming and technically challenging use of statistical parametric mapping (4,5,7,22,23).…”

Neuronal surface antibody-mediated encephalopathy as manifestation of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

“…In our case, 18F-FDG brain PET-CT demonstrated diffuse cortical and subcortical hypometabolism that completely normalized following immunosuppressive therapy. Functional imaging with 18F-FDG brain PET-CT recently emerged as a useful tool for improving the diagnosis of some auto-immune encephalitis (Celliers et al, 2016;Dong et al, 2016;Lagarde and Guedj, 2015;Morbelli et al, 2017). Whether it could also bring relevant complementary information to integrate in the diagnostic algorithm of CNS-GVHD, especially in patients with normal MRI, is not known and has to be explored in the future.…”

Current status and perspectives of PET molecular imaging in Mexico

“…4,5 Perhaps the most useful and best known metabolic pathway in proliferation studies is glucose metabolism (glycolysis), which in turn is the most widely used (and the first one employed) in PET. In these studies, a glucose analogue is labelled with 18 Fluor ( 18 F), thus becoming 18 F-fluorodeoxyglucose (FDG), a radiopharmaceutical that is highly useful in oncology, neurology and cardiology and for assessment of other pathologies, such as infectious and inflammatory processes. 6 Due to its widespread use, availability and millions of performed studies, this radiopharmaceutical has become PET/CT resource par excellence.…”

“…In addition to radiopharmaceutical physiological biodistribution, the large extent of lymph node and bone metastatic disease is observed. On the right, computed tomography and PET/CT pelvic region axial sections of a patient with prostate cancer referred for assessment with 18 F-PSMA due to biochemical recurrence. CT scan shows no detectable abnormalities while in the same of PET/CT fusion section radiopharmaceutical focal uptake is observed at the left iliac level (arrow), with no detectable anatomical changes, consistent with known primary tumor activity.…”